{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:32:23Z","timestamp":1784154743887,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["2018\/851233-1"],"award-info":[{"award-number":["2018\/851233-1"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>\n              <jats:italic>Plasmodium falciparum<\/jats:italic> is the main cause of malaria in North-Eastern (NE) states of India. Artemether\u2013lumefantrine (AL) was introduced as first-line therapy against uncomplicated <jats:italic>P. falciparum<\/jats:italic> cases in 2013 after the emergence of resistance to sulfadoxine\u2013pyrimethamine. The aim of the study was to assess the therapeutic efficacy of AL and status of molecular markers in the circulating parasites.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Therapeutic efficacy of AL was assessed in NE states as per World Health Organization guidelines. Patients with <jats:italic>P. falciparum<\/jats:italic> positive peripheral blood smear were enrolled and treated with AL and clinical and parasitological parameters were monitored over a 28-day follow-up period. Furthermore, the <jats:italic>pfmdr1<\/jats:italic>, <jats:italic>pfdhfr<\/jats:italic>, <jats:italic>pfdhps<\/jats:italic> and <jats:italic>pfk13<\/jats:italic> genes were amplified and sequenced for mutation analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 231 cases were enrolled and therapeutic efficacy was determined in 215 (93.1%) patients who completed their 28\u00a0days\u2019 follow-up while 10 patients withdrew and 6 were lost to follow up during study. Overall 99.5% and 98.6% of adequate clinical and parasitological response was observed with and without PCR correction, respectively. Only three cases (1.4%) of late parasitological failure were observed in Mizoram site. One case of recrudescence and two cases of reinfection were detected by <jats:italic>msp1<\/jats:italic> and <jats:italic>msp2<\/jats:italic> genotyping. Mutation analysis showed the 15.8%, 100%, 90.5% mutants in <jats:italic>pfmdr1<\/jats:italic>, <jats:italic>pfdhfr<\/jats:italic> and <jats:italic>pfdhps<\/jats:italic> gene respectively and three non-synonymous mutations were also found in <jats:italic>pfk13<\/jats:italic>gene.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study reports that AL is efficacious against uncomplicated <jats:italic>P. falciparum<\/jats:italic> cases in NE states of India. However, prevalence of mutations in molecular marker associated with anti-malarial resistance (<jats:italic>pfmdr1<\/jats:italic>, <jats:italic>pfdhfr<\/jats:italic>, <jats:italic>pfdhps<\/jats:italic> and <jats:italic>pfk13<\/jats:italic>) gene indicate possible emergence of drug resistance. This is to underline the fact that the drug is efficacious for now, but rising mutations indicate that continuous monitoring is essential for effective treatment regime.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12936-025-05338-1","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T13:08:23Z","timestamp":1743512903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic efficacy of artemether\u2013lumefantrine in North-Eastern states of India and prevalence of drug resistance-associated molecular markers"],"prefix":"10.1186","volume":"24","author":[{"given":"Shreelekha","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup Kumar","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushrikanta","family":"Khandai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disphikha","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soni","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Kumar","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparup","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup R.","family":"Anvikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Kumar","family":"Bharti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"5338_CR1","unstructured":"WHO. World Malaria Report, 2023. Geneva: World Health Organization; 2024. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024."},{"key":"5338_CR2","unstructured":"National Center for Vector Borne Disease Control (NVBDCP). Malaria situation in India; 2023. https:\/\/ncvbdc.mohfw.gov.in\/WriteReadData\/l892s\/833563291720527717.pdf"},{"key":"5338_CR3","first-page":"175","volume":"5","author":"PN Sehgal","year":"1973","unstructured":"Sehgal PN, Sharma MI, Sharma SL, Gogai S. Resistance to chloroquine in falciparum malaria in Assam State. India J Commun Dis. 1973;5:175\u201380.","journal-title":"India J Commun Dis"},{"key":"5338_CR4","first-page":"109","volume":"18","author":"S Das","year":"1981","unstructured":"Das S, Barkakaty BN, Roy JR, Guha AK, Rastogi KC, Dwivedi SR, et al. Pyrimethamine in combination with sulfadoxine or sulfalene in P. falciparum infected cases in India. Indian J Malariol. 1981;18:109\u201316.","journal-title":"Indian J Malariol"},{"key":"5338_CR5","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1056\/NEJMc1713777","volume":"379","author":"S Das","year":"2018","unstructured":"Das S, Saha B, Hati AK, Roy S. Evidence of artemisinin-resistant Plasmodium falciparum malaria in eastern India. N Engl J Med. 2018;379:1962\u20134.","journal-title":"N Engl J Med"},{"key":"5338_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105562","volume":"9","author":"PK Mohapatra","year":"2014","unstructured":"Mohapatra PK, Sarma DK, Prakash A, Bora K, Ahmed MA, Sarma B, et al. Molecular evidence of increased resistance to anti-folate drugs in Plasmodium falciparum in North-East India: a signal for potential failure of artemisinin plus sulphadoxine-pyrimethamine combination therapy. PLoS ONE. 2014;9: e105562.","journal-title":"PLoS ONE"},{"key":"5338_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/1475-2875-13-284","volume":"13","author":"N Mishra","year":"2014","unstructured":"Mishra N, Kaitholia K, Srivastava B, Shah NK, Narayan JP, Dev V, et al. Declining efficacy of artesunate plus sulphadoxine-pyrimethamine in northeastern India. Malar J. 2014;13:284.","journal-title":"Malar J"},{"key":"5338_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","volume":"37","author":"NJ White","year":"1999","unstructured":"White NJ, Van Vugt M, Ezzet FD. Clinical pharmacokinetics and pharmacodynamics of artemether\u2013lumefantrine. Clin Pharmacokinet. 1999;37:105\u201325.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"5338_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/1475-2875-8-S1-S3","volume":"8","author":"ZG Premji","year":"2009","unstructured":"Premji ZG. Coartem\u00ae: the journey to the clinic. Malar J. 2009;8(Suppl 1):S3.","journal-title":"Malar J"},{"key":"5338_CR10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1128\/AAC.43.2.418","volume":"43","author":"B Pradines","year":"1999","unstructured":"Pradines B, Tall A, Fusai T, Spiegel A, Hienne R, Rogier C, et al. In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Antimicrob Agents Chemother. 1999;43:418\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"5338_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1021\/cb300454t","volume":"8","author":"JM Combrinck","year":"2013","unstructured":"Combrinck JM, Mabotha TE, Ncokazi KK, Ambele MA, Taylor D, Smith PJ, et al. Insights into the role of heme in the mechanism of action of antimalarials. ACS Chem Biol. 2013;8:133\u20137.","journal-title":"ACS Chem Biol"},{"key":"5338_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijpddr.2019.10.001","volume":"11","author":"J Chhibber-Goel","year":"2019","unstructured":"Chhibber-Goel J, Sharma A. Profiles of Kelch mutations in Plasmodium falciparum across South Asia and their implications for tracking drug resistance. Int J Parasitol Drugs Drug Resist. 2019;11:49\u201358.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5338_CR13","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/cid\/ciy1038","volume":"69","author":"S Das","year":"2019","unstructured":"Das S, Manna S, Saha B, Hati AK, Roy S. Novel pfkelch13 gene polymorphism associates with artemisinin resistance in eastern India. Clin Infect Dis. 2019;69:1144\u201352.","journal-title":"Clin Infect Dis"},{"key":"5338_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12639-021-01425-7","volume":"46","author":"LK Murmu","year":"2022","unstructured":"Murmu LK, Barik TK. An analysis of Plasmodium falciparum-K13 mutations in India. J Parasit Dis. 2022;46:296\u2013303.","journal-title":"J Parasit Dis"},{"key":"5338_CR15","first-page":"1073","volume":"51","author":"V Dev","year":"2003","unstructured":"Dev V, Bhattacharyya PC, Talukdar R. Transmission of malaria and its control in the northeastern region of India. JAssoc Physicians India. 2003;51:1073\u20136.","journal-title":"JAssoc Physicians India"},{"key":"5338_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2021.106040","volume":"222","author":"V Dev","year":"2021","unstructured":"Dev V, Manguin S. Defeating malaria in the North-East region: the forerunner for malaria elimination in India. Acta Trop. 2021;222: 106040.","journal-title":"Acta Trop"},{"key":"5338_CR17","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"5338_CR18","unstructured":"NVBDCP. National drug policy 2013. National vector borne disease control programme; New Delhi; 2013. http:\/\/www.nvbdcp.gov.in\/Doc\/National-Drug-Policy-2013.pdf. Accessed 20 Oct 2019."},{"key":"5338_CR19","first-page":"283","volume":"58","author":"G Snounou","year":"1993","unstructured":"Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, et al. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. MolBiochemParasitol. 1993;58:283\u201392.","journal-title":"MolBiochemParasitol"},{"key":"5338_CR20","first-page":"33","volume":"15","author":"PK Bharti","year":"2010","unstructured":"Bharti PK, Alam MT, Boxer R, Shukla MM, Gautam SP, Sharma YD, et al. Therapeutic efficacy of chloroquine and sequence variation in pfcrt gene among patients with falciparum malaria in central India. Trop Med Int Health. 2010;15:33\u201340.","journal-title":"Trop Med Int Health"},{"key":"5338_CR21","unstructured":"Nicholas KB, Nicholas HJ. GeneDoc: a tool for editing and annotating multiple sequence alignments. ScienceOpen. 1997."},{"key":"5338_CR22","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/molbev\/msx248","volume":"34","author":"J Rozas","year":"2017","unstructured":"Rozas J, Ferrer-Mata A, S\u00e1nchez-DelBarrio JC, Guirao-Rico S, Librado P, Ramos-Onsins SE, et al. DnaSP 6: DNA sequence polymorphism analysis of large data sets. Mol Biol Evol. 2017;34:3299\u2013302.","journal-title":"Mol Biol Evol"},{"key":"5338_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller JD, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263\u20135.","journal-title":"Bioinformatics"},{"key":"5338_CR24","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619\u201320.","journal-title":"N Engl J Med"},{"key":"5338_CR25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning T, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"5338_CR26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/1475-2875-10-378","volume":"10","author":"PW Gething","year":"2011","unstructured":"Gething PW, Patil AP, Smith DL. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J. 2011;10:378.","journal-title":"Malar J"},{"key":"5338_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001398","volume":"10","author":"VI Carrara","year":"2013","unstructured":"Carrara VI, Lwin KM, Phyo AP. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999\u20132011: an observational study. PLoS Med. 2013;10: e1001398.","journal-title":"PLoS Med"},{"key":"5338_CR28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1186\/s12936-016-1555-4","volume":"15","author":"PK Bharti","year":"2016","unstructured":"Bharti PK, Shukla MM, Ringwald P, Krishna S, Singh PP, Yadav A, et al. Therapeutic efficacy of artemether\u2013lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria from three highly malarious states in India. MalarJ. 2016;15:498.","journal-title":"MalarJ"},{"key":"5338_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12936-021-03762-7","volume":"20","author":"S Krishna","year":"2021","unstructured":"Krishna S, Mishra S, Tiwari P, Vishwakarma AK, Khandai S, Shrivastava S, et al. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in four malaria endemic states of India. Malar J. 2021;20:229.","journal-title":"Malar J"},{"key":"5338_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264339","volume":"17","author":"K Marwa","year":"2022","unstructured":"Marwa K, Kapesa A, Baraka V, Konje E, Kidenya B, Mukonzo J, et al. Therapeutic efficacy of artemether\u2013lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: a systematic review and meta-analysis. PLoS ONE. 2022;17: e0264339.","journal-title":"PLoS ONE"},{"key":"5338_CR31","first-page":"81","volume":"61","author":"S Sinha","year":"2024","unstructured":"Sinha S, Sharma S, Singh K, Swarnkar D, Ahmed N, Rajput P, et al. Efficacy and safety of artemisinin combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria across international borders of India. J Vector Borne Dis. 2024;61:81\u20139.","journal-title":"J Vector Borne Dis"},{"key":"5338_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12936-024-04931-0","volume":"23","author":"BE Ngasala","year":"2024","unstructured":"Ngasala BE, Chiduo MG, Mmbando BP, Francis FT, Bushukatale S, Makene T, et al. Efficacy and safety of artemether\u2013lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2019. MalarJ. 2024;23:101.","journal-title":"MalarJ"},{"key":"5338_CR33","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/infdis\/jis747","volume":"207","author":"M Malmberg","year":"2013","unstructured":"Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Bjorkman A, et al. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis. 2013;207:842\u20137.","journal-title":"J Infect Dis"},{"key":"5338_CR34","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1038\/ncomms11553","volume":"7","author":"MI Veiga","year":"2016","unstructured":"Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gn\u00e4dig N, Uhlemann AC, et al. Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat Commun. 2016;7:11553.","journal-title":"Nat Commun"},{"key":"5338_CR35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12936-016-1490-4","volume":"15","author":"A Mbaye","year":"2016","unstructured":"Mbaye A, Dieye B, Ndiaye YD, Bei AK, Muna A, Deme AB, et al. Selection of N86F184D1246 haplotype of Pfmrd1 gene by artemether\u2013lumefantrine drug pressure on Plasmodium falciparum populations in Senegal. Malar J. 2016;15:433.","journal-title":"Malar J"},{"key":"5338_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13104-019-4269-1","volume":"12","author":"E Achol","year":"2019","unstructured":"Achol E, Ochaya S, Malinga GM, Edema H, Echodu R. High prevalence of Pfmdr-1 N86 and D1246 genotypes detected among febrile malaria outpatients attending Lira Regional Referral Hospital, Northern Uganda. BMC Res Notes. 2019;12:235.","journal-title":"BMC Res Notes"},{"key":"5338_CR37","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1086\/587845","volume":"197","author":"C Lynch","year":"2008","unstructured":"Lynch C, Pearce R, Pota H, Cox J, Abeku TA, Rwakimari J, et al. Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. J Infect Dis. 2008;197:1598\u2013604.","journal-title":"J Infect Dis"},{"key":"5338_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000055","volume":"6","author":"RJ Pearce","year":"2009","unstructured":"Pearce RJ, Pota H, Evehe MS, B\u00e2 EH, Mombo-Ngoma G, Malisa AL, et al. Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med. 2009;6: e1000055.","journal-title":"PLoS Med"},{"key":"5338_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12038-017-9706-5","volume":"42","author":"NP Sarmah","year":"2017","unstructured":"Sarmah NP, Sarma K, Bhattacharyya DR, Sultan AA, Bansal D, Singh N, et al. Antifolate drug resistance: novel mutations and haplotype distribution in dhps and dhfr from Northeast India. J Biosci. 2017;42:531\u20135.","journal-title":"J Biosci"},{"key":"5338_CR40","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12936-019-3022-5","volume":"18","author":"A Kumar","year":"2019","unstructured":"Kumar A, Singh SP, Bhatt R, Singh V. Genetic profiling of the Plasmodium falciparum parasite population in uncomplicated malaria from India. MalarJ. 2019;18:385.","journal-title":"MalarJ"},{"key":"5338_CR41","first-page":"1363969","volume":"2","author":"S Kale","year":"2024","unstructured":"Kale S, Uplekar SM, Bandyopadhyay N, Rao PN, Ali SZ, Sharma SK, et al. Antimalarial drug resistance profiling of Plasmodium falciparum infections in India using Ion Torrent deep sequencing. FrontMalar. 2024;2:1363969.","journal-title":"FrontMalar"},{"key":"5338_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107071","volume":"63","author":"A Sinha","year":"2024","unstructured":"Sinha A, Kar S, Chauhan C, Yadav CP, Kori L. Meta-analysis on Plasmodium falciparum sulfadoxine-pyrimethamine resistance-conferring mutations in India identifies hot spots for genetic surveillance. Int J Antimicrob Agents. 2024;63: 107071.","journal-title":"Int J Antimicrob Agents"},{"key":"5338_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"5338_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10969-016-9205-1","volume":"17","author":"GP Singh","year":"2016","unstructured":"Singh GP, Goel P, Sharma A. Structural mapping of Kelch13 mutations associated with artemisinin resistance in malaria. J Struct Funct Genom. 2016;17:51\u20136.","journal-title":"J Struct Funct Genom"},{"key":"5338_CR45","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nrmicro.2017.161","volume":"16","author":"K Haldar","year":"2018","unstructured":"Haldar K, Bhattacharjee S, Safeukui I. Drug resistance in Plasmodium. Nat Rev Microbiol. 2018;16:156\u201370.","journal-title":"Nat Rev Microbiol"},{"key":"5338_CR46","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/20477724.2017.1331875","volume":"111","author":"S Mishra","year":"2017","unstructured":"Mishra S, Bharti PK, Shukla MM, Ali NA, Kashyotia SS, Kumar A, et al. Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+ sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012\u20132014. Pathog Glob Health. 2017;111:186\u201394.","journal-title":"Pathog Glob Health"},{"key":"5338_CR47","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.1260867","volume":"347","author":"J Straimer","year":"2015","unstructured":"Straimer J, Gn\u00e4dig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015;347:428\u201331.","journal-title":"Science"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05338-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05338-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05338-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T21:54:24Z","timestamp":1743717264000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05338-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5338"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05338-1","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional ethics committee of ICMR-NIRTH, Jabalpur. All study participants provided written informed consent prior to their participation according to Indian Council of Medical Research (ICMR), New Delhi, India guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}